Europe Enzyme Replacement Therapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)

Code: BMIRE00027277 | Pages: 180 | Industry: Biotechnology | Date: Oct 2022 | Type: Regional

The enzyme replacement therapy market in Europe is expected to grow from US$ 2,900.09 million in 2022 to US$ 4,206.54 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.

 

Rapid Regulatory Approval with Other Benefits for Drugs with Orphan Drug Designation

 

A condition that affects fewer than 200,000 people nationwide is termed as orphan disease. Fabry's disease, Pompe disease, and Hunter syndrome are among a few examples. European Medicines Agency (EMA) deals with approving orphan drugs. For instance, according to EMA, if a product that has an orphan drug designation receives EMA marketing approval for the indication, the product is entitled to orphan market exclusivity; this means the EMA may not approve any other application to market a similar drug for the same indication for 10 years. Furthermore, in March 2016, the EMA launched the Priority Medicines ("PRIME") scheme to facilitate the development of product candidates in indications for which few or no therapies currently exist. The PRIME scheme also provides several benefits to drug producers once a candidate medicine is selected. Below mentioned are the benefits provided by the EMA:

 

•   Appoints a rapporteur from the Committee for Medicinal Products for Human Use (CHMP) and help to build knowledge ahead of a marketing-authorization application

•   Early and proactive regulatory dialogue with the EMA to guide the overall development plan and regulatory strategy

•   Offers scientific advice at key development milestones, involving additional stakeholders, such as health-technology-assessment bodies, to facilitate quicker access for patients to the new medicine

•   Confirms potential for accelerated assessment at the time of an application for marketing authorization

 

Therefore, owing to the benefit and incentives associated with drugs designated as orphan drugs, key players operating in the market are putting efforts into developing drugs for orphan diseases. For instance, Amicus Therapeutics, Inc. recently obtained an orphan medicinal product designation in Europe from the EMA for Galafold to treat Fabry disease and the combination product—ATB200/AT2221—for treating Pompe disease. Additionally, in September 2020, Amicus Therapeutics, Inc. was granted PRIME designation for AT-GTX-501 for the treatment of CLN6 or Batten disease. Thus, the rapid regulatory approval with other marketing benefits for the drug with orphan drug designation is driving the market growth.

 

Market Overview

 

The Europe enzyme replacement therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany is considered among the fastest-growing enzyme replacement therapy markets in Europe. The growing importance of enzyme replacement therapy is due to rising healthcare expenditure, which is aiding the market growth in Germany. The federal statistical office reported an increase in the health expenditure in Germany, which aids in research and development in the healthcare sector. For instance, in April 2022, the Federal Statistical Office (Destatis) confirmed that health spending in 2020 was 26.8 billion euros, or 6.5% higher than in 2019. Moreover, according to German Trade and Invest (GTAI), on average, more than 710 companies are engaged in the biotechnology sector. Germany has experienced a boom in innovative pharmaceutical companies, drug manufacturers, contract research organizations (CROs), and small-medium-sized biopharmaceutical companies over the years. In February 2020, as per the paper “Developments in the treatment of Fabry disease” published in Wiley Online Library, a new form of ERT- moss-aGal, for the treatment of Fabry Disease (FD) was developed by Greenovation biopharmaceuticals, in Germany. Moreover, the rising government health expenditure and increasing biotechnology and pharmaceutical companies are boosting the enzyme replacement therapy market, which is also boosting the growth of the Europe enzyme replacement therapy market.

 

 Europe Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)

 Europe Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)

Get more information on this report :

                     

 

Europe Enzyme Replacement Therapy Market Segmentation

 

The Europe enzyme replacement therapy market is segmented into enzyme type, therapeutic conditions, route of administration, end user, and country.

  • Based on enzyme type, the market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. The other enzymes segment registered the largest market share in 2022.

By therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's disease, MPS, Pompe's disease, SCID, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2022.

 

In terms of route of administration, the market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2022.

 

From end user point of reference, the market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2022.

  • Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, rest of Europe. Germany dominated the market in 2022.

Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc are the leading companies operating in the enzyme replacement therapy market in Europe.   

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Enzyme Replacement Therapy Market – By Enzyme Type

1.3.2        Europe Enzyme Replacement Therapy Market – By Therapeutic Conditions

1.3.3        Europe Enzyme Replacement Therapy Market – By Route of Administration

1.3.4        Europe Enzyme Replacement Therapy Market – By End User

1.3.5        Europe Enzyme Replacement Therapy Market – By Country

2.           Europe Enzyme Replacement Therapy Market– Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Europe Enzyme Replacement Therapy Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Europe – PEST Analysis

4.3         Expert Opinion

5.           Europe Enzyme Replacement Therapy Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of Lysosomal Storage Diseases (LSDs)

5.1.2        Rapid Regulatory Approval with Other Benefits for Drug with Orphan Drug Designation

5.2         Market Restraints

5.2.1        Cutthroat Competition among Market Players

5.3         Market Opportunities

5.3.1        Increasing Partnerships and Collaborations to Synergize the Business

5.4         Future Trends

5.4.1        Innovative Developments in ERT

5.5         Impact Analysis

6.           Enzyme Replacement Therapy Market– Europe Analysis

6.1         Europe Enzyme Replacement Therapy Market Revenue Forecast and Analysis

7.           Europe Enzyme Replacement Therapy Market Revenue and Forecasts To 2028– by Enzyme Type

7.1         Overview

7.2         Europe Enzyme Replacement Therapy Market, By Enzyme Type 2021 & 2028 (%)

7.3         Alglucosidase Alfa

7.3.1        Overview

7.3.2        Alglucosidase Alfa Revenue and Forecast to 2028 (US$ Million)

7.4         Agalsidase Beta

7.4.1        Overview

7.4.2        Agalsidase Beta - Revenue and Forecast to 2028 (US$ Million)

7.5         Imiglucerase

7.5.1        Overview

7.5.2        Imigluceras - Revenue and Forecast to 2028 (US$ Million)

7.6         Idursulfase

7.6.1        Overview

7.6.2        Idursulfase - Revenue and Forecast to 2028 (US$ Million)

7.7         Galsulfase

7.7.1        Overview

7.7.2        Galsulfase - Revenue and Forecast to 2028 (US$ Million)

7.8         Velaglucerase Alfa

7.8.1        Overview

7.8.2        Velaglucerase Alfa - Revenue and Forecast to 2028 (US$ Million)

7.9         Other Enzymes

7.9.1        Overview

7.9.2        Other Enzymes - Revenue and Forecast to 2028 (US$ Million)

8.           Europe Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Therapeutic Conditions

8.1         Overview

8.2         Europe Enzyme Replacement Therapy Market, By Therapeutic Conditions 2021 & 2028 (%)

8.3         Gaucher's Disease

8.3.1        Overview

8.3.2        Gaucher's Disease - Market Revenue and Forecast to 2028 (US$ Million)

8.4         Fabry's Disease

8.4.1        Overview

8.4.2        Fabry's Disease - Market Revenue and Forecast to 2028 (US$ Million)

8.5         Mucopolysaccharidosis (MPS)

8.5.1        Overview

8.5.2        MPS - Market Revenue and Forecast to 2028 (US$ Million)

8.6         Pompe's Disease

8.6.1        Overview

8.6.2        Pompe's Disease - Market Revenue and Forecast to 2028 (US$ Million)

8.7         SCID

8.7.1        Overview

8.7.2        SCID - Market Revenue and Forecast to 2028 (US$ Million)

8.8         Other Therapeutic Conditions

8.8.1        Overview

8.8.2        Other Therapeutic Conditions - Market Revenue and Forecast to 2028 (US$ Million)

9.           Europe Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Route of Administration

9.1         Overview

9.2         Europe Enzyme Replacement Therapy Market, By Route of Administration 2021 & 2028 (%)

9.3         Parenteral

9.3.1        Overview

9.3.2        Parenteral - Market Revenue and Forecast to 2028 (US$ Million)

9.4         Oral

9.4.1        Overview

9.4.2        Oral - Market Revenue and Forecast to 2028 (US$ Million)

10.        Europe Enzyme Replacement Therapy Market Analysis– By End User

10.1      Overview

10.2      Europe Enzyme Replacement Therapy Market, By End User 2021 & 2028 (%)

10.3      Hospitals

10.3.1     Overview

10.3.2     Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)

10.4      Infusion Centers

10.4.1     Overview

10.4.2     Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)

10.5      Others

10.5.1     Overview

10.5.2     Others - Market Revenue and Forecasts To 2028 (US$ Million)

11.        Europe Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 – Country Analysis

11.1      Europe: Enzyme Replacement Therapy Market

11.1.1     Overview

11.1.3     Europe: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)

11.1.3.1       Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.1       Overview

11.1.3.1.2       Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.3       Germany: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.1.4       Germany: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.1.5       Germany: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.1.6       Germany: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

11.1.3.2       UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.1       Overview

11.1.3.2.2       UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.3       UK: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.2.4       UK: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.2.5       UK: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.2.6       UK: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

11.1.3.3       France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.1       Overview

11.1.3.3.2       France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.3       France: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.3.4       France: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.3.5       France: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.3.6       France: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

11.1.3.4       Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.1       Overview

11.1.3.4.2       Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.4.3       Italy: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.4.4       Italy: Enzyme Replacem4ent Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.4.5       Italy: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.4.6       Italy: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

11.1.3.5       Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.1       Overview

11.1.3.5.2       Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.5.3       Spain: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.5.4       Spain: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.5.5       Spain: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.5.6       Spain: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

11.1.3.6       Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.1       Overview

11.1.3.6.2       Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.6.3       Rest of Europe: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)

11.1.3.6.4       Rest of Europe: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)

11.1.3.6.5       Rest of Europe: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)

11.1.3.6.6       Rest of Europe: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)

12.        Europe Enzyme Replacement Therapy Market–Industry Landscape

12.1      Overview

12.2      Inorganic Growth Strategies

12.2.1     Overview

12.3      Organic Growth Strategies

12.3.1     Overview

13.        Company Profiles

13.1      Sanofi

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      BioMarin Pharmaceutical Inc.

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Takeda Pharmaceutical Company Limited

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      AbbVie Inc.

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Alexion Pharmaceuticals, Inc. (AstraZeneca)

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     WOT Analysis

13.6.6     Key Developments

13.7      Amicus Therapeutics

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Recordati S.p.A.

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

13.9      CHIESI Farmaceutici S.p.A.

13.9.1     Key Facts

13.9.2     Business Description

13.9.3     Products and Services

13.9.4     Financial Overview

13.9.5     SWOT Analysis

13.9.6     Key Developments

13.10   Pfizer Inc.

13.10.1  Key Facts

13.10.2  Business Description

13.10.3  Products and Services

13.10.4  Financial Overview

13.10.5  SWOT Analysis

13.10.6  Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

 

 

LIST OF TABLES

Table 1.             Germany Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 2.             Germany Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 3.             Germany Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 4.             Germany Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 5.             UK Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 6.             UK Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 7.             UK Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 8.             UK Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 9.             France Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 10.          France Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 11.          France Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 12.          France Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 13.          Italy Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Italy Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 15.          Italy Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 16.          Italy Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 17.          Spain Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Spain Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 19.          Spain Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 20.          Spain Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 21.          Rest of Europe Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Rest of Europe Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)

Table 23.          Rest of Europe Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)

Table 24.          Rest of Europe Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)

Table 25.          Recent Inorganic Growth Strategies in the Enzyme Replacement Therapy Market

Table 26.          Recent Organic Growth Strategies in the Enzyme Replacement Therapy Market

Table 27.          Glossary of Terms

 

 

LIST OF FIGURES

Figure 1.           Europe Enzyme Replacement Therapy Market Segmentation

Figure 2.           Europe Enzyme Replacement Therapy Market Segmentation, By Country

Figure 3.           Europe Enzyme Replacement Therapy Market Overview

Figure 4.           Europe Enzyme Replacement Therapy Market, By Enzyme Type

Figure 5.           Europe Enzyme Replacement Therapy Market, By Country

Figure 7.           Europe: PEST Analysis

Figure 8.           Expert Opinion

Figure 9.           Europe Impact Analysis

Figure 10.        Europe Enzyme Replacement Therapy Market– Revenue Forecast and Analysis – 2020- 2028

Figure 11.        Europe Enzyme Replacement Therapy Market, by Enzyme Type 2021 & 2028 (%)

Figure 12.        Europe Alglucosidase Alfa Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Europe Agalsidase Beta - Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        Europe Imiglucerase - Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        Europe Idursulfase - Revenue and Forecasts to 2028 (US$ Million)

Figure 16.        Europe Galsulfase - Revenue and Forecasts to 2028 (US$ Million)

Figure 17.        Europe Velaglucerase Alfa - Revenue and Forecasts to 2028 (US$ Million)

Figure 18.        Europe Other Enzymes - Revenue and Forecasts to 2028 (US$ Million)

Figure 19.        Europe Enzyme Replacement Therapy Market, by Therapeutic Conditions 2021 & 2028 (%)

Figure 20.        Europe Gaucher's Disease - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 21.        Europe Fabry's Disease - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 22.        Europe MPS - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 23.        Europe Pompe's Disease - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 24.        Europe SCID - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 25.        Europe Other Therapeutic Conditions - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 26.        Europe Enzyme Replacement Therapy Market, by Route of Administration 2021 & 2028 (%)

Figure 27.        Europe Parenteral - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28.        Europe Oral - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 29.        Europe Enzyme Replacement Therapy Market, by End User 2021 & 2028 (%)

Figure 30.        Europe Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)

Figure 31.        Europe Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)

Figure 32.        Europe Others- Market Revenue and Forecasts To 2028 (US$ Million)

Figure 33.        Europe: Enzyme Replacement Therapy Market, by Key Country – Revenue (2021) (US$ Million)

Figure 34.        Europe: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)

Figure 35.        Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39.        Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40.        Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

  1. Sanofi.
  2. BioMarine Pharmaceutical Inc.
  3. Takeda Pharmaceutical Company Limited.
  4. AbbVie Inc.
  5. Janssen Pharmaceutical ( Johnson & Johnson Services,Inc.).
  6. Alexion Pharmaceutical, Inc.(AstaZeneca).
  7. Amicus Therapeutics.
  8. Recordati S.p.A.
  9. CHIESI farmaceutici S.p.A.
  10. Pfizer Inc.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000